Horizon Therapeutics Fields Takeover Interest From Pharma Giants

82
Comment
Favorite

Horizon Therapeutics Fields Takeover Interest From Pharma Giants

The Wall Street Journal2022-11-30

Drugmaker Horizon Therapeutics PLC said it is fielding takeover interest, as large pharmaceutical companies compete for fast-growing medicines to fuel sales.Horizon, which develops medicines for rare ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

ParrySKLow
·2022-11-30
Thanks
Reply
1
Report
ericbqlee
·2022-11-30
🙂
Reply
2
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1138317312?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-11-30 08:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138317312","market":"us","top_or_hot":-1,"title":"Horizon Therapeutics Fields Takeover Interest From Pharma Giants","media":"The Wall Street Journal","content":"<div>\n<p>Drugmaker Horizon Therapeutics PLC said it is fielding takeover interest, as large pharmaceutical companies compete for fast-growing medicines to fuel sales.Horizon, which develops medicines for rare ...</p>\n\n<a href=\"https://www.wsj.com/articles/horizon-therapeutics-fields-takeover-interest-from-pharma-giants-11669756919?mod=hp_lista_pos3\">Source Link</a>\n\n</div>\n","source":"wsj_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Horizon Therapeutics Fields Takeover Interest From Pharma Giants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHorizon Therapeutics Fields Takeover Interest From Pharma Giants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-30 08:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/horizon-therapeutics-fields-takeover-interest-from-pharma-giants-11669756919?mod=hp_lista_pos3><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Drugmaker Horizon Therapeutics PLC said it is fielding takeover interest, as large pharmaceutical companies compete for fast-growing medicines to fuel sales.Horizon, which develops medicines for rare ...</p>\n\n<a href=\"https://www.wsj.com/articles/horizon-therapeutics-fields-takeover-interest-from-pharma-giants-11669756919?mod=hp_lista_pos3\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMGN","symbol_name":"安进","start_time":0,"source_url":"https://www.wsj.com/articles/horizon-therapeutics-fields-takeover-interest-from-pharma-giants-11669756919?mod=hp_lista_pos3","article_id":"1138317312","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138317312","pubTimestamp":1669769721,"sourceInfo":{"source_id":"wsj_highlight","name":"The Wall Street Journal"},"weMediaInfo":null,"summary":"Drugmaker Horizon Therapeutics PLC said it is fielding takeover interest, as large pharmaceutical co","collect":0,"end_time":0,"defaultTopTitle":"wsj.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMGN":"安进","HZNP":"Horizon Pharma","SNY":"赛诺菲安万特","JNJ":"强生"},"translate_title":"Horizon Therapeutics Fields收购制药巨头的兴趣","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":0.9,"HZNP":0.9,"JNJ":0.9,"SNY":0.9},"content_text":"Drugmaker Horizon Therapeutics PLC said it is fielding takeover interest, as large pharmaceutical companies compete for fast-growing medicines to fuel sales.Horizon, which develops medicines for rare and immune diseases, said it is “engaged in highly preliminary discussions with Amgen Inc., [Johnson & Johnson’s] Janssen Global Services, LLC and Sanofi”SA, confirming an earlier Wall Street Journal report on takeover interest.A deal for Horizon would be big. The company had a market value of almost $18 billion as of the close of trading Tuesday and, with a typical takeover premium, could fetch a price well over $20 billion. The shares rose some 30% after hours on the news.Any tie-up, however, is uncertain and a deal may not emerge.Horizon is Nasdaq-listed, but headquartered in Ireland and with operations in Dublin, Deerfield, Ill., and a new facility in Rockville, Md. It develops medicines to treat rare autoimmune and severe inflammatory diseases that are currently sold mostly in the U.S. Its biggest drug, Tepezza, is used to treat thyroid eye disease, an affliction characterized by progressive inflammation and damage to tissues around the eyes.Last year, revenue from the product more than doubled, driving the company’s overall net sales 47% higher to $3.23 billion. Horizon said this month that annual global net sales of the drug are targeted to eventually peak at more than $4 billion as the company aims to win approval to sell it in Europe and Japan.That type of growth is attractive to big pharmaceutical companies—with many sitting on big piles of cash—that rely on acquisitions as a key strategy to expand sales. Many big drugmakers are looking for new sources of revenue to offset losses when some of their main products lose patent protection.This month, Johnson & Johnson struck a $16.6 billion dealto acquire heart-device makerAbiomedInc. to bolster sales of its medical-gear division, which had been lagging those of its pharmaceutical unit.Merck & Co. followed that deal with its own, agreeing to buy blood-cancer biotech Imago BioSciencesInc. increase; green up pointing trianglefor $1.35 billion, ahead of the patent expiration of its cancer immunotherapy called Keytruda.Pfizer Inc. meanwhile, agreed in August to buy Global Blood Therapeutics Inc.for $5.4 billion, in a deal that would give the big drugmaker a foothold in the treatment of sickle-cell disease.Horizon’s other drugs include Krystexxa for treating gout, a form of inflammatory arthritis, and Ravicti, a prescription used to manage high blood levels caused by a genetic condition known as urea cycle disorder.Drugs treating rare diseases have emerged as a large source of pharmaceutical sales, even though there aren’t a lot of patients, because they can command high prices that health insurers have been willing to pay.Sanofi, J&J and Pfizer are among the big drugmakers that have built portfolios of rare-disease therapies.Any deal for Horizon, if it happened this year, could rank as the largest healthcare acquisition globally in 2022, ahead of the Johnson & Johnson-Abiomed tie-up. The selloff in stocks this year amid rising interest rates, whileputting a damper on deal activity, has also made some companies more attractive targets. At the stock’s peak about a year ago, Horizon was valued at roughly $27 billion.Horizon said that, in accordance with Irish takeover rules, possible bidders must announce whether or not they intend to make an offer by Jan. 10.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[{"id":9962621005,"gmtCreate":1669771173107,"gmtModify":1676538239471,"author":{"id":"3582026529372712","authorId":"3582026529372712","name":"ParrySKLow","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":3,"crmLevelSwitch":1},"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9962621005","repostId":1138317312,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9962665436,"gmtCreate":1669770648326,"gmtModify":1676538239256,"author":{"id":"4101424154342900","authorId":"4101424154342900","name":"ericbqlee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"🙂","listText":"🙂","text":"🙂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9962665436","repostId":1138317312,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":82,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}